Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 5/20 | 0.42 |
| ▸ | EGFR | P00533 | 5/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 6/20 | 0.41 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 5/20 | 0.40 |
| ▸ | ABL1 | P00519 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17090652 | 0.85 | NUDT14 (0.42) | EGFRPIK3CDPIK3CBPIK3CGKDM4E | |
| SCHEMBL24096482 | 0.75 | PIK3CD (0.55) | EGFRPIK3CDPIK3CBPIK3CGKDM4E | |
| SCHEMBL24096486 | 0.69 | SRC (0.50) | EGFRPIK3CDPIK3CBPIK3CGKDM4E | |
| SCHEMBL13020102 | 0.67 | EGFR (0.47) | CSF1REGFRPIK3CDPIK3CBPIK3CG | |
| SCHEMBL3403614 | 0.67 | KDM4E (0.55) | EGFRPIK3CDPIK3CBKDM4ENPC1 | |
| SCHEMBL17264219 | 0.66 | SRC (0.52) | EGFRKDM4ENPC1HTTRAB9A | |
| SCHEMBL13367477 | 0.66 | KDM4C (0.46) | CSF1REGFRTSHR | |
| SCHEMBL3785235 | 0.65 | PIK3CD (0.51) | EGFRPIK3CDPIK3CBPIK3CGKDM4E | |
| SCHEMBL13063879 | 0.65 | SRC (0.61) | CSF1REGFRPIK3CDPIK3CBPIK3CG | |
| SCHEMBL23997145 | 0.65 | SRC (0.55) | EGFRPIK3CDPIK3CBPIK3CGKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9862722-B2 | Inhibitors of Bruton's tyrosine kinase | PHARMACYCLICS LLC (US) | 2018-01-09 | — | — | US | disclosed |
| US-20150329550-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2015-11-19 | — | — | US | disclosed |
| US-9138436-B2 | Inhibitors of Bruton's tyrosine kinase | PHARMACYCLICS LLC (US) | 2015-09-22 | — | — | US | disclosed |
| US-20130018032-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2013-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150329550-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, ABL2 | CSF1R 2589/4885EGFR 947/4885PIK3CD 534/4885 |
| US-20130018032-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, ABL2 | CSF1R 2589/4885EGFR 947/4885PIK3CD 534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.